DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE

Detalhes bibliográficos
Main Authors:	McLaren, J, Hall, C, Luqmani, R
Formato:	Journal article
Publicado em:	2004

Registos relacionados

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
Por: McLaren, J, et al.
Publicado em: (2003)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
Por: Salisbury, E, et al.
Publicado em: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
Por: Salisbury, E, et al.
Publicado em: (2004)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
Por: Salisbury, E, et al.
Publicado em: (2003)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
Por: Salisbury, E, et al.
Publicado em: (2003)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
Por: McLaren, J, et al.
Publicado em: (2001)

Explaining fatigue in ANCA-associated vasculitis.
Por: Basu, N, et al.
Publicado em: (2013)

Explaining fatigue in ANCA-associated vasculitis
Por: Basu, N, et al.
Publicado em: (2013)

Towards diagnostic criteria for the ANCA-associated vasculitides.
Por: Luqmani, R
Publicado em: (2007)

Predictors of renal involvement in ANCA associated vasculitis
Por: Kronbichler, A, et al.
Publicado em: (2018)

Damage assessment in ANCA-associated vasculitis.
Por: Bhamra, K, et al.
Publicado em: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
Por: Luqmani, R
Publicado em: (2013)

Outcome measures in ANCA-associated vasculitis.
Por: Suppiah, R, et al.
Publicado em: (2010)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
Por: McLaren, J, et al.
Publicado em: (2000)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Por: Jones, R, et al.
Publicado em: (2010)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
Por: Basu, N, et al.
Publicado em: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
Por: Basu, N, et al.
Publicado em: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis
Por: Basu, N, et al.
Publicado em: (2014)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
Por: Luqmani, R
Publicado em: (2013)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
Por: Basu, N, et al.
Publicado em: (2012)

Cutaneous manifestations of ANCA-associated vasculitis
Por: Chiesafuxench, Z, et al.
Publicado em: (2016)

Cardiovascular outcomes in ANCA associated vasculitis
Por: Mukhtyar, C, et al.
Publicado em: (2008)

Markers for work disability in ANCA-associated vasculitis
Por: Basu, N, et al.
Publicado em: (2013)

Diagnosis and management of ANCA associated vasculitis.
Por: Berden, A, et al.
Publicado em: (2012)

USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS
Por: Mukhtyar, C, et al.
Publicado em: (2009)

Treatment of renal manifestations of ANCA-associated vasculitis
Por: Kresimir Galesic, et al.
Publicado em: (2013-01-01)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
Por: Ana Teresa Domingos, et al.
Publicado em: (2019-10-01)

The need for diagnostic criteria in systemic vasculitis
Por: Suppiah, R, et al.
Publicado em: (2011)

ANCA-associated vasculitis: Where can we go from here?
Por: Luqmani, R
Publicado em: (2010)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
Por: Arnold, D, et al.
Publicado em: (2010)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
Por: Jones, R, et al.
Publicado em: (2009)

Clinical features and outcomes of ANCA-associated renal vasculitis
Por: Sidy Mohamed Seck, et al.
Publicado em: (2012-01-01)

Diagnosis and assessment of systemic vasculitis.
Por: McLaren, J, et al.
Publicado em: (2002)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
Por: Suppiah, R, et al.
Publicado em: (2011)

Long-term survival of ANCA-associated vasculitis
Por: Flossmann, O, et al.
Publicado em: (2009)

New ACR/EULAR 2022 classification criteria for ANCA-associated vasculitis
Por: T. V. Beketova
Publicado em: (2023-10-01)

Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients
Por: Peining Zhou, et al.
Publicado em: (2022-01-01)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
Por: Pearce, F, et al.
Publicado em: (2016)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
Por: Suppiah, R, et al.
Publicado em: (2011)

Comparison of disease activity measures for ANCA-associated vasculitis.
Por: Merkel, P, et al.
Publicado em: (2004)